Michael Thomas Henderson, Chief Executive Officer at Apogee Therapeutics, Inc. (APGE), sold 20,000 shares at $82.21 ($1.7M) on 2026-06-10, disclosed to the SEC on 2026-06-12.
Scheduled sale ($1.7M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $82.21 | 6,770 | $557K | 33.4% |
| 2 | $82.78 | 7,654 | $634K | 38.0% |
| 3 | $84.18 | 1,080 | $91K | 5.5% |
| 4 | $85.19 | 1,577 | $134K | 8.1% |
| 5 | $86.27 | 2,305 | $199K | 11.9% |
| 6 | $86.89 | 614 |
| $53K |
| 3.2% |
| Total | $83.38 avg | 20,000 | $1.7M | 100% |
| Filing → |
| SYRE | SELL | 2026-06-23 | $2.0M | — | Filing → |
| APGE | SELL | 2026-05-15 | $1.6M | — | Filing → |
| SYRE | SELL | 2026-05-08 | $6.0M | — | Filing → |